Literature DB >> 29331575

Validation of MRI to TRUS registration for high-dose-rate prostate brachytherapy.

Eric Poulin1, Karim Boudam2, Csaba Pinter3, Samuel Kadoury4, Andras Lasso3, Gabor Fichtinger3, Cynthia Ménard5.   

Abstract

PURPOSE: The objective of this study was to develop and validate an open-source module for MRI to transrectal ultrasound (TRUS) registration to support tumor-targeted prostate brachytherapy. METHODS AND MATERIALS: In this study, 15 patients with prostate cancer lesions visible on multiparametric MRI were selected for the validation. T2-weighted images with 1-mm isotropic voxel size and diffusion weighted images were acquired on a 1.5T Siemens imager. Three-dimensional (3D) TRUS images with 0.5-mm slice thickness were acquired. The investigated registration module was incorporated in the open-source 3D Slicer platform, which can compute rigid and deformable transformations. An extension of 3D Slicer, SlicerRT, allows import of and export to DICOM-RT formats. For validation, similarity indices, prostate volumes, and centroid positions were determined in addition to registration errors for common 3D points identified by an experienced radiation oncologist.
RESULTS: The average time to compute the registration was 35 ± 3 s. For the rigid and deformable registration, respectively, Dice similarity coefficients were 0.87 ± 0.05 and 0.93 ± 0.01 while the 95% Hausdorff distances were 4.2 ± 1.0 and 2.2 ± 0.3 mm. MRI volumes obtained after the rigid and deformable registration were not statistically different (p > 0.05) from reference TRUS volumes. For the rigid and deformable registration, respectively, 3D distance errors between reference and registered centroid positions were 2.1 ± 1.0 and 0.4 ± 0.1 mm while registration errors between common points were 3.5 ± 3.2 and 2.3 ± 1.1 mm. Deformable registration was found significantly better (p < 0.05) than rigid registration for all parameters.
CONCLUSIONS: An open-source MRI to TRUS registration platform was validated for integration in the brachytherapy workflow.
Copyright © 2017 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HDR brachytherapy; MRI; Open source; Prostate; Registration; Ultrasound

Mesh:

Year:  2018        PMID: 29331575     DOI: 10.1016/j.brachy.2017.11.018

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  5 in total

1.  Learning deep similarity metric for 3D MR-TRUS image registration.

Authors:  Grant Haskins; Jochen Kruecker; Uwe Kruger; Sheng Xu; Peter A Pinto; Brad J Wood; Pingkun Yan
Journal:  Int J Comput Assist Radiol Surg       Date:  2018-10-31       Impact factor: 2.924

2.  Technical Note: Patient-morphed mesh-type phantoms to support personalized nuclear medicine dosimetry - a proof of concept study.

Authors:  Jason S Lewis; Adam L Kesner; Lukas M Carter; Juan Camilo Ocampo Ramos; Wesley E Bolch
Journal:  Med Phys       Date:  2021-03-09       Impact factor: 4.071

3.  Prostate specific membrane antigen positron emission tomography for lesion-directed high-dose-rate brachytherapy dose escalation.

Authors:  Christopher W Smith; Ryan Alfano; Douglas Hoover; Kathleen Surry; David D'Souza; Jonathan Thiessen; Irina Rachinsky; John Butler; Jose A Gomez; Mena Gaed; Madeleine Moussa; Joseph Chin; Stephen Pautler; Glenn S Bauman; Aaron D Ward
Journal:  Phys Imaging Radiat Oncol       Date:  2021-07-30

4.  Image-guided Raman spectroscopy navigation system to improve transperineal prostate cancer detection. Part 2: in-vivo tumor-targeting using a classification model combining spectral and MRI-radiomics features.

Authors:  David Orlando Grajales Lopera; Fabien Picot; Roozbeh Shams; Frédérick Dallaire; Guillaume Sheehy; Stephanie Alley; Maroie Barkati; Guila Delouya; Jean-Francois Carrier; Mirela Birlea; Dominique Trudel; Frédéric Leblond; Cynthia Ménard; Samuel Kadoury
Journal:  J Biomed Opt       Date:  2022-09       Impact factor: 3.758

Review 5.  Image guidance in radiation therapy for better cure of cancer.

Authors:  Vincent Grégoire; Matthias Guckenberger; Karin Haustermans; Jan J W Lagendijk; Cynthia Ménard; Richard Pötter; Ben J Slotman; Kari Tanderup; Daniela Thorwarth; Marcel van Herk; Daniel Zips
Journal:  Mol Oncol       Date:  2020-06-29       Impact factor: 6.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.